Gastrointestinal Bleeding Treatment Market – By Product (Endoscopic Hemostatic Devices [Mechanical, Thermal], Closure Devices), GI Tract Division (Upper, Lower), Onset (Acute, Chronic), End-use (Hospitals, ASCs) - Global Forecast (2024 – 2032)

Gastrointestinal Bleeding Treatment Market Size

Gastrointestinal Bleeding Treatment Market size was valued at USD 808 million in 2023 and is expected to reach USD 1.6 billion by 2032, growing at a CAGR of 7.9% over the analysis period. One of the primary drivers is rising cases of gastrointestinal disorders such as peptic ulcers, gastritis, and colorectal cancer, which lead to bleeding in the digestive tract.
 

Additionally, the rising geriatric population, who are more prone to gastrointestinal bleeding due to age-related changes in the digestive system, is contributing to market growth. For instance, studies have shown that the rate of admission for acute upper GI bleeding increases significantly with age, with a 30-fold increase between the third and ninth decades of life. Moreover, technological advancements in endoscopy procedures and diagnostic imaging techniques have further fuelled market expansion by increasing the diagnosis and treatment adoption of gastrointestinal bleeding.
 

Gastrointestinal bleeding, also known as GI bleeding, refers to any bleeding that occurs in the gastrointestinal tract, which includes the oesophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Gastrointestinal bleeding treatment refers to the medical interventions aimed at stopping or managing bleeding in the gastrointestinal tract. This can include various approaches depending on the cause and severity of the bleeding, such as endoscopic procedures, surgery, and supportive care. The goal is to stabilize the patient, control bleeding, and prevent complications.
 

Gastrointestinal Bleeding Treatment Market Trends

• Increasing incidence of gastrointestinal bleeding (GIB) is a significant driver of the market.
   
• Several factors such as rising aging population coupled with increasing prevalence of gastrointestinal disorders such as peptic ulcers, gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), as well as the growing use of NSAID’s is contribution to the increasing cases of GI tract bleeding.
   
• For instance, as per the National Institute of Health (NIH), peptic ulcer disease (PUD) affects four million people worldwide annually and has an estimated lifetime prevalence of 5−10% in the general population.
   
• Additionally, lifestyle factors such as smoking, excessive alcohol consumption, and poor dietary habits also play a role in the development of GI bleeding.
   
• Thus, as the incidence of GI bleeding continues to rise, there is a growing need for effective treatments to manage this condition and its complications, driving the growth of the market.
   

Gastrointestinal Bleeding Treatment Market Analysis

Based on product, the market is segmented into endoscopic hemostatic devices, closure devices, and other products. The endoscopic hemostatic devices segment is further divided into endoscopic mechanical devices and endoscopic thermal devices. The endoscopic hemostatic devices segment dominated the market with revenue of USD 498.8 million in 2023.
 

• Endoscopic hemostatic devices are widely used due to their high efficacy and minimally invasive nature. These devices are favored for their ability to achieve hemostasis quickly and effectively, reducing the need for more invasive surgical interventions.
   
• These devices offer precise control and easy application, making them preferred options for both acute and chronic bleeding cases.
   
• Moreover, advancements in endoscopic technology, including improved device designs and better visualization capabilities, enhance the efficacy and safety of these devices, further boosting their market share.

Based on GI tract division, the gastrointestinal bleeding treatment market is segmented into upper GI tract and lower GI tract. The upper GI tract segment held a dominant market share of 72.4% in 2023.
 

• Higher market share of upper GI tract bleeding can be attributed to the high incidence of peptic ulcers that develop in the stomach or the upper part of the small intestine (duodenum).
   
• Additionally, rising cases of gastritis, esophagitis, Mallory-Weiss tears (tears in the mucous membrane at the junction of the esophagus and stomach), and certain cancers contribute to upper GI bleeding, further enhancing the segment expansion.
   

Based on onset, the gastrointestinal bleeding treatment market is classified into acute and chronic. The acute segment is expected to reach USD 1.1 billion by 2032.
 

• Acute GI tract bleeding, characterized by the sudden onset of bleeding in the GI tract, often requires immediate medical attention and intervention.
   
• Additionally, the rising prevalence of risk factors such as NSAID use, alcohol consumption, and Helicobacter pylori infection has led to a higher incidence of acute GI bleeding cases.
   
• Furthermore, the availability of innovative hemostatic agents and the growing adoption of minimally invasive surgical procedures have further expanded the market for acute GI bleeding treatments.
   

Based on end-use, the gastrointestinal bleeding treatment market is classified into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to grow at 7.8% CAGR between 2024- 2032.
 

• The hospitals segment holds a substantial share in the market, driven by its pivotal role as a primary healthcare provider for acute and chronic conditions.
   
• Hospitals offer a comprehensive range of treatment options, including endoscopic interventions and surgical procedures, making them a prominent end-user of GI tract bleeding treatments.
   
• Further, their advanced infrastructure, specialized medical staff, and access to cutting-edge technologies contribute significantly to their dominance in the market.
   
• Additionally, hospitals often serve as referral centers for complex cases, further solidifying their position in the gastrointestinal bleeding treatment landscape.

In 2023, North America held a market share of 41.6% in the global gastrointestinal bleeding treatment market and is expected to reach USD 635.7 million by 2032.
 

• High regional growth can be attributed to the high prevalence of gastrointestinal disorders in the region. For instance, as per the CDC, peptic ulcer is a common illness in the U.S. affecting over 6 million persons each year.
   
• Additionally, well-established healthcare infrastructure, increasing adoption of advanced treatment options, strong presence of key market players, coupled with extensive research and development activities, further contribute to its dominant market position.
   
• Moreover, favorable reimbursement policies and increasing healthcare expenditure supports the growth of the market in North America.
   

Gastrointestinal Bleeding Treatment Market Share

The market is characterized by the presence of established players offering a range of products for gastrointestinal bleeding treatment. Key players compete on factors such as product diversity, product efficacy, safety profile, pricing, distribution networks, and brand reputation. Continuous focus on innovation, strategic partnerships, mergers, and acquisitions are common strategies employed by market players to gain a competitive edge in this dynamic and evolving market.
 

Prominent players operating in the gastrointestinal bleeding treatment industry are as mentioned below:

• Boston Scientific Corporation
• CONMED Corporation
• Cook Group
• ERBE Elektromedizin GmbH
• Medtronic PLC
• Olympus Corporation
• Ovesco Endoscopy AG
• Pfizer Inc.
• STERIS PLC
• US Medical Innovations
   

Gastrointestinal Bleeding Treatment Industry News

• In September 2022, Medtronic plc received U.S. Food and Drug Administration clearance of the Nexpowder endoscopic hemostasis system. This helped the company expand its product offerings in the U.S.
   
• In May 2018, Cook Medical received U.S. FDA clearance to market its hemospray device for the treatment of some types of non-variceal gastrointestinal (GI) tract bleeding. The product is indicated to control both upper and lower GI bleeding and helped the company increase its sales.
   

The gastrointestinal bleeding treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Endoscopic hemostatic devices
  • Endoscopic mechanical devices
  • Endoscopic thermal devices
• Closure devices
• Other products

Market, By GI Tract Division

• Upper GI tract
• Lower GI tract

Market, By Onset

• Acute
• Chronic

Market, By End-use

• Hospitals
• Ambulatory surgical centers (ASCs)
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa